Framing the potential of public frameshift peptides as immunotherapy targets in colon cancer
I. T. Spaanderman, F. S. Peters, A. Jongejan, E. J. Redeker, C. J. A. Punt, A. D. Bins
The paper identifies 20 frameshift peptides in MSI colon cancer patients that could serve as immunotherapy targets, covering most patients and Lynch syndrome cases.
bioRxiv · Mar 26, 2020Cancer Biology